Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Cracker Barrel's controversial rebrand sparks backlash and a viral AI-generated joke about the White House, leading to the company's self-aware response and a case study in corporate PR recovery.
Altria's Q3 earnings beat estimates, but shares fell on weak outlook and persistent category challenges.
Novo Nordisk launches $9B bid to acquire U.S. obesity biotech Metsera, intensifying the race for next-generation weight-loss treatments.
Cracker Barrel's controversial rebrand sparks backlash and a viral AI-generated joke about the White House, leading to the company's self-aware response and a case study in corporate PR recovery.
Altria's Q3 earnings beat estimates, but shares fell on weak outlook and persistent category challenges.